Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
September 12, 2022
Genethon to Present Its Latest Gene Therapy Research Advancements in Neuromuscular Diseases at the International Myology 2022 Congress
Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), announced today its scientists will make five oral presentations and display 18 posters of their latest research on neuromuscular diseases at the 7th International… (read more)
May 16, 2022
Genethon’s R&D to be Featured in Multiple Presentations at ASGCT Annual Meeting, May 16-19
April 4, 2022
Genethon Joins U.S. Bespoke Gene Therapy Consortium Dedicated to Finding Treatments for Ultra-Rare Diseases
February 28, 2022
Gene Therapies Continue to Emerge as Effective Treatments for Rare Diseases, But Complex Challenges Remain
To mark International Rare Disease Day, Genethon identifies the most urgent priorities in overcoming these obstacles.
(read more)February 10, 2022
Genethon’s Lentiviral Vector-Based Gene Therapy Demonstrates Long-Term Safety and Efficacy for Wiskott-Aldrich Syndrome
January 6, 2022
Genethon Announces Publication of Results paving the way for Gene Therapy for XLH, a Skeletal Disorder
The AAV-based therapy targets the liver’s hepatocytes to express therapeutic proteins for secretion into the bloodstream and long-lasting treatment of the rare disease.
(read more)October 20, 2021
Genethon Presents Significant Advances in Gene Therapy at European Society for Gene and Cell Therapy, Oct 19-22, 2021
June 28, 2021
Preliminary results of clinical trial for rare liver disease Crigler-Najjar syndrome presented at ESGCT congress
April 23, 2021
Genethon announces First Patient dosed in Clinical Trial of Investigational Gene therapy GNT 0004 for Duchenne Muscular Dystrophy
February 28, 2021
Genethon, 30 years of pioneering research and innovation in treating rare diseases
February 10, 2021
Genethon and WhiteLab Genomics join forces to enhance gene therapy through artificial intelligence
February 3, 2021
Genethon is delighted about the launch of a gene therapy clinical trial for late-onset Pompe disease
December 2, 2020
Genethon gets the green light from the ANSM to start an innovative gene therapy trial for Duchenne muscular dystrophy
September 21, 2020
Genethon welcomes the submission to EMA of Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics, a french biopharma company, just submitted to EMAMarketing Autorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON), a rare, mitochondrial genetic disease, caused by mutation in the ND4 mitochondrial gene.
(read more)June 10, 2020
